| Species |
Cynomolgus |
| Protein Construction |
PDGF R beta/CD140b (Leu33-Lys531)
Accession # A0A2K5TUS0 |
His |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized PDGF R beta/CD140b, His, Cynomolgus at 2μg/ml (100μl/well) on the plate can bind AntiPDGFRB Antibody, hFc Tag. Test result was comparable to standard batch |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
57.49 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 75-105 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Platelet-derived growth factor receptor (PDGFR) signaling is involved in proliferation and survival in a wide array of cell types.PDGFR-β signalling, via TGF-β signalling, may be crucial for restoration of BBB integrity after cerebral ischemia and therefore represents a novel potential therapeutic target. |
| Synonyms |
PDGF-R-beta; PDGFR-beta; PDGFRB; PDGF R beta; PDGFR-2; PDGFR-β |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
